Assessing High Dose ICS in COPD Patients with Elevated FeNO Are ShortTerm Gains Real

Introduction:

Emerging research challenges the assumption that inhaled corticosteroids (ICS) uniformly benefit all chronic obstructive pulmonary disease (COPD) patients. A recent single-centre study explored whether COPD patients with fractional exhaled nitric oxide (FeNO) concentrations above 35 parts per billion (ppb) show measurable pulmonary improvements following a 28-day high-dose ICS treatment. Despite targeted inclusion criteria, the findings underscore the complexity of corticosteroid responsiveness in this subset.
Visit https://www.allergyimmunoljournal.com/ for more groundbreaking research in respiratory health and immunology.

Study Highlights and Findings

• Study Type: Single-arm pre–post trial
• Location: Kameda Medical Center, Japan
• Participants: 20 COPD patients with FeNO > 35 ppb
• Intervention: Budesonide (200 μg, 8 puffs/day) for 28 days
• Primary Outcome: Change in FEV1 after 28 days
• Key Result:
  • Mean increase in FEV1: +340 mL, but not statistically significant (p = 0.122)
  • No significant improvements in %FEV1, %FVC, or COPD Assessment Test scores

Clinical Relevance and Biomarker Considerations

Despite theoretical expectations, elevated FeNO levels did not predict strong improvements in lung function. This aligns with findings by the American Thoracic Society (ATS) which stress that FeNO should not be solely relied upon to assess ICS responsiveness in COPD patients. Blood eosinophil count and IgE levels, while considered potential indicators of treatment efficacy, also failed to correlate significantly with improved outcomes in this study.

Subgroup and Post-Hoc Observation

• FeNO > 50 ppb: Mean FEV1 improvement = 160 mL (not significant)
• Blood eosinophils > 300×10⁴/μL: FEV1 improvement = 250 mL
• Total IgE > 300 IU/mL: FEV1 improvement = 590 mL (only 1/7 patients showed marked benefit)

A detailed analysis can be found in our main journal article journal.aaai.1001020.

Study Limitations & Future Research

• Sample Size: Only 20 participants with no control group
• Compliance Issues: 50% had incomplete asthma diaries
• Short Duration: 28-day intervention may not capture long-term changes
• Patient Profile: Exclusively Japanese cohort; limited generalizability

Further multicentre trials with larger, more diverse populations are necessary to validate FeNO as a viable biomarker for ICS treatment responsiveness.

Explore Related Insights

• Learn more about diagnostic challenges in asthma-COPD overlap
• Visit our Pulmonology category for evidence-based COPD management strategies
• Explore eosinophil-guided therapies in our latest allergy and immunology research

Additionally, visit https://www.allergyimmunoljournal.com/ to discover other important developments in chronic respiratory care.

Call-to-Action

Explore more studies at https://www.allergyimmunoljournal.com/ and join the conversation by sharing your thoughts in the comments below

Disclaimer: This content is generated using AI assistance and should be reviewed for accuracy and compliance before considering this article and its contents as a reference. Any mishaps or grievances raised due to the reusing of this material will not be handled by the author of this article.